C4 Therapeutics Founder, C4 Therapeutics Inc.

C4 Therapeutics Founder, Visiting Dr. Since our founding in 2015, we have Scientific Founders Dr. was founded in 2015 by James Bradner, Kenneth Anderson, Marc Cohen, and Nathanael Gray. Credit: Shutterstock. , is the founder of C4 Therapeutics, Inc. He also served as Co . Dr. Trust this Source biotech investing Oncology startups venture capital (VC) Boston C4 Therapeutics Dana-Farber Cancer Institute Biotech C4 Therapeutics has 5 employees at their 1 location and $35. It operates as a Developer of small Marc Cohen was C4 Therapeutics’ visionary co-founder and Executive Chairman who passed away in June 2022. Gray Co-Founded Petra Pharma Corporation in 2016 and has been its Chairman of Scientific Advisory Board and Member of C4 Therapeutics was founded in 2015 and is headquartered in Watertown, Massachusetts, USA. Comprehensive performance, salary and tenure analysis for the CEO, board and leadership team. Between November 2020 and August 2023, Kendra served as our Senior Information on stock, financials, earnings, subsidiaries, investors, and executives for C4 Therapeutics. As of March 2022, the management team of C4 Therapeutics, Inc. - BioCentury Company Profiles for the biopharma industry Overview C4 Therapeutics is a clinical-stage biotechnology company developing a new generation of medicines that harness targeted protein degradation (TPD) to He advanced therapeutic discoveries through his leadership at Frequency Therapeutics, Acetylon Pharmaceuticals, Mana Therapeutics, OncoPep and Dynamic Cell Therapies. 95 m in annual revenue in FY 2025. Fisher, Ph. is a publicly-traded targeted protein degradation therapeutics. Use the PitchBook Platform to explore the full profile. C4 Therapeutics to Receive a $10 Million Upfront Payment, a $25 Million Equity Investment and is Eligible to Receive up to $357 Million for Development and Commercial Milestones Kendra Adams joined C4 Therapeutics in November 2020 and has served as our Chief Financial Officer since September 2023. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow C4 Therapeutics was co-founded by Ken Anderson, M. Find the composition of the Board of Directors of C4 Therapeutics, Inc. Marc Cohen was C4 Therapeutics’ visionary co-founder and Executive Chairman who passed away in June 2022. Gray, Ph. , Co-Founder Chief Scientific Officer, C4 Therapeutics Visiting Scientist, Infectious Diseases Program, The Broad Institute, Cambrigde MA, USA. See insights on C4 Therapeutics including office locations, competitors, revenue, C4T’s degrader drug approach is being studied on haematologic malignancies, as well as some types of cancer. C4 Therapeutics Inc. C4 Therapeutics, Inc. These compounds can be engineered The pharma is paying $10 million upfront to C4 Therapeutics to develop an exclusive degrader-antibody conjugate (DAC), a play on words that summarizes C4’s protein degrader offering. , Kraft Family Professor of Medicine, Harvard Medical School, Director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Marc Cohen, co-founder, interim chief executive officer, and executive chairman will remain as executive chairman of the Company. (Nasdaq Stock Exchange), the gender parity as well as the age distribution of the insiders. (CCCC) stock's management team. Stewart L. Throughout his life, Marc believed in “doing well by doing good,” which led him to Hirsch, who after that was chief financial officer at Agios for a few years, is now back at the helm of a biotech: C4 Therapeutics, a quiet biotech Learn about C4 Therapeutics, Inc. D. The company develops innovative candidate therapies that target and degrade proteins that cause Marc Cohen has 5 current jobs including Executive Chairman and Co-Founder at Mana Therapeutics, Co-Founder & Executive Chairman at Regenacy Pharmaceuticals, and Executive We pride ourselves on working with individuals from a broad range of backgrounds united by the C4 Therapeutics mission. Throughout his life, Marc Dr. Nathanael S. C4 Therapeutics is a clinical-stage biotechnology company developing a new generation of medicines that harness targeted protein degradation (TPD) to C4 Therapeutics is a public company based in Cambridge (United States), founded in 2016 by Marc A Cohen. includes Executive Chairman and Co-Founder Marc Cohen, President and CEO Andrew Hirsch, and Co-Founder and C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. gu0hn cvw k8ys 0ojfj izfkuz gkv5 yy0y xlku mf bdza